Recent Updates
Recently added Catalysts
NAGE Positive Sentiment

Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Niagen Bioscience, Inc. reported strong financial results for Q3 2026, with total net sales of $27.2 million, driven primarily by $23.3 million from its Tru Niagen® product. The company also noted a 13% increase in direct to consumer sales compared to the previous year. The gross margin was reported at 62%.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total net sales reached $27.2 million.
  • Direct to consumer sales grew by 13% year-over-year.
  • Gross margin stood at 62%.

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026. Third Quarter 2026 Financial and Business Highlights Total net sales of $27.2 million, including $23.3 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 13% year-over-year. Gross margin of 62.

Frequently Asked Questions

What were Niagen's total net sales for Q3 2026?

Total net sales reached $27.2 million.

How much did Tru Niagen contribute to sales?

Tru Niagen contributed $23.3 million to total sales.

What was the growth rate of direct consumer sales?

Direct to consumer sales grew by 13% year-over-year.

What was the gross margin reported by Niagen?

The gross margin was reported at 62%.

ShareAdd on Google
Tags: NAGE NAD+ healthy aging Tru Niagen financial results
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$67M liquidity · $0M/mo burn
Low dilution risk
Lead asset
NiagenPlusPhase 1
Fatigue →